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The epidemic of illicit intravenous drug use (IVDU) in the 
United States has been accompanied by a surge in drug 
overdose deaths and infectious sequelae. Candida albicans 
infections were associated with injection of contaminated im-
pure brown heroin in the 1970s–1990s; however, candidiasis 
accompanying IVDU became considerably rarer as the pu-
rity of the heroin supply increased. We reviewed cases of 
candidemia occurring over a recent 7-year period in persons 
>14 years of age at a tertiary care hospital in central Massa-
chusetts. Of the 198 patients with candidemia, 24 cases oc-
curred in patients with a history of IVDU. Compared with non-
IVDU patients, those with a history of IVDU were more likely 
to have non-albicans Candida, be co-infected with hepatitis 
C, and have end-organ involvement, including endocarditis 
and osteomyelitis. Thus, IVDU appears to be reemerging as 
a risk factor for invasive candidiasis.
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SYNOPSIS
Invasive fungal infections resulting from candidiasis are notable causes of illness and death in both adults 
and pediatric patients (1–4). C. albicans accounts for ap-
proximately half the cases of candidemia. For example, in 
a study of 2,019 candidemia cases during 2004–2008, C. 
albicans was responsible for 46% of the cases, followed 
by C. glabrata (26%), C. parapsilosis (16%), C. tropica-
lis (8%), and C. krusei (3%) (1). Risk factors for invasive 
Candida infections include immunocompromised status, 
central venous catheters, broad-spectrum antimicrobial 
drugs, kidney disease requiring dialysis, and genitourinary 
and gastrointestinal surgery or procedures (5).
Opioid addiction has emerged as an increasingly cru-
cial public health problem in the United States. More than 
50,000 persons died from drug overdoses in the United 
States in 2015, an increase of >500% since 1990 (6). Mas-
sachusetts has been one of the states hardest hit by this epi-
demic; an estimated 2,190 opioid-related deaths occurred 
in 2016, which is a ≈4-fold increase since 2010, when 
560 such deaths occurred (7). In addition to deaths from 
overdoses, infectious sequelae from intravenous drug use 
(IVDU) commonly occur, including acute infections such 
as abscesses at injection sites and endocarditis and chronic 
infections such as HIV and hepatitis C.
During the 1970s–1990s, outbreaks were reported of 
C. albicans infections in intravenous drug users who used 
impure brown heroin (8,9). The source of the Candida was 
thought to be contaminated lemon juices used to dissolve 
the heroin (10–12). Clinical manifestations in the affected 
patients included nodular and pustular cutaneous lesions, 
chorioretinitis, and osteoarticular infection (8,9,11). After 
the 1990s, the general purity of heroin supplies increased, 
negating the need to use acidic sources such as lemon juice 
as solvents; thus, the problem of candidiasis associated 
with IVDU mostly disappeared. However, rare case reports 
of candidiasis syndromes associated with IVDU, such as 
endophthalmitis associated with injecting contaminated bu-
prenorphine, continued to appear in the literature (13,14).
Recently, we noticed an apparent increase in cas-
es of invasive candidiasis associated with IVDU at 
UMassMemorial Medical Center, Worcester, Massachu-
setts, USA. We therefore retrospectively reviewed all cases 
of candidemia seen at the hospital over a 7-year period. We 
compared cases in patients with a history of IVDU with those 
without such a history with regard to demographic, epide-
miologic, clinical, laboratory, and microbiological features.
Methods
UMassMemorial Medical Center is a 781-bed academic 
medical center affiliated with the University of Massachu-
setts Medical School and located in central Massachusetts. 
The study was approved by the University of Massachu-
setts Medical School (UMMS) Institutional Review Board 
(IRB). Patients >14 years of age with a positive blood cul-
ture for Candida species during January 1, 2010–January 
31, 2017, were included in the study. We excluded patients 
<14 years of age, as they were felt to be unlikely to have 
a history of IVDU. The protocol approved by the IRB also 
excluded the study of prisoners; however, none of the pa-
tients was excluded for this reason.
We identified cases of candidemia by a query of the 
hospital electronic medical records (EMRs) using Thera-
doc (Premier Inc., Charlotte, NC, USA). We then reviewed 
the EMRs of the patients with candidemia for any history of 
IVDU; we classified cases as IVDU and non-IVDU on the 
basis of this chart review. We included cases in the IVDU 
group if there was any history of IVDU, even if remote. 
We reviewed admission notes, infectious diseases consult 
notes, psychiatry consult notes, discharge notes, and toxi-
cology screens. We then conducted a further review of the 
EMRs to extract data on the epidemiology, risk factors, 
clinical manifestations, microbiology, laboratory findings, 
and outcomes. The IRB protocol forbade contacting the pa-
tients directly.
We performed Candida speciation using standard 
techniques, including the Vitek 2-Yeast System, Vitek-
MS, and API 20C (bioMérieux, Marcy l’Étoile, France). 
We compared the variables in the tables between the IVDU 
and non-IVDU populations using the Fisher exact test for 
categorical variables and the Wilcoxon rank sum test for 
continuous variables. These tests are nonparametric and 
avoid the need for large sample sizes. We defined statisti-
cal significance as a p value <0.05.
Results
Epidemiologic Data and Risk Factors 
During January 1, 2010–January 31, 2017, a total of 198 
patients had positive blood cultures for Candida species. 
Using the criteria noted in the previous section, we cat-
egorized 24 (12%) patients as being in the IVDU group 
and 174 (88%) patients in the non-IVDU group. Salient 
baseline characteristics of the study population are shown 
in Table 1. Patients in the IVDU group were significantly 
younger and more likely to have had a positive test for 
hepatitis C compared with patients in the non-IVDU group 
(p<0.001 for both variables). Although the numbers were 
small, a significantly higher percentage of patients in the 
IVDU group had prosthetic valves (p = 0.013). All 3 of 
the patients in the IVDU group with a prosthetic valve had 
valve replacement because of prior episodes of endocardi-
tis. None of the other baseline characteristics we studied 
differed significantly between the groups. Only 1 patient 
had known HIV infection.
We compared the prevalence of many of the estab-
lished risk factors for candidemia in IVDU and non-IVDU 
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groups (Table 1). Although the differences were not sta-
tistically significant, patients in the non-IVDU group were 
more likely to have diabetes (31.6% v. 12.5%) and a history 
of malignancy (24.1% vs. 8.3%). We noted no significant 
differences between the 2 groups with regard to systemic 
immunosuppression, genitourinary procedures, kidney dis-
ease requiring dialysis, central intravenous lines, gastroin-
testinal surgery procedures, or history of broad-spectrum 
antimicrobial drug use.
Of the 24 cases of IVDU-associated candidemia re-
corded during the 7-year period of the study, only 2 oc-
curred during the first 2 years. In contrast, 9 cases occurred 
in 2016, the last year of the study (Figure). The number 
of candidemia cases was not associated with diminished 
IVDU in the last 2 years of the study.
Features of Patients with Candidemia and History  
of IVDU
Details about the patients with a history of IVDU are pro-
vided in Table 2. Most of the patients gave a history of 
use of heroin, cocaine, or both. However, prescription opi-
oids were also commonly found when toxicology screens 
were obtained.
Organ System Involvement
We determined the prevalence of brain abscesses, osteo-
myelitis, retinitis, skin lesions, septic emboli to the lungs, 
and endocarditis (Table 3). Although endocarditis and os-
teomyelitis were seen infrequently, the IVDU group had a 
significantly higher percentage of cases of these 2 diseases 
compared with the non-IVDU group.
Candida Species
C. albicans was isolated from the bloodstream in a signifi-
cantly higher percentage of non-IVDU patients compared 
with IVDU patients (Table 4). In contrast, the percentage of 
Candida isolates identified as C. parapsilosis was signifi-
cantly higher in the IVDU group. Other Candida species 
were isolated, mostly commonly C. glabrata and C. tropi-
calis, but their distribution was not significantly different 
between the IVDU and non-IVDU groups. Two patients in 
each group were co-infected with 2 Candida species.
Outcome Data
Mortality rates and length of hospitalization were low-
er in the IVDU group compared with the non-IVDU 
group (Table 5). However, the differences were not statisti-
cally significant.
Discussion
Our data establish that, in the setting of the ongoing opioid 
epidemic, candidemia appears to have emerged as a serious 
clinical problem in the IVDU population in central Mas-
sachusetts. Major differences appear, however, between the 
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Table 1. Baseline characteristics and risk factors for candidemia, categorized by IVDU and non-IVDU groups, among patients at a 
tertiary care hospital, Massachusetts, USA, 2010–2017* 
Characteristics IVDU Non-IVDU p value 
No. patients 24 174  
Median age (IQR) 43.5 (14.8) 64.0 (19.0) <0.001 
Female sex† 6 (25.0) 70 (40.2) 0.183 
Prosthetic valve 3 (12.5) 2 (1.2) 0.013 
Hepatitis C 14 (58.3) 14 (8.1) <0.001 
HIV 0 1 (0.6) 1.00 
History of malignancy 2 (8.3) 42 (24.1) 0.114 
Diabetes 3 (12.5) 55 (31.6) 0.058 
Systemic immunosuppression‡ 3 (12.5) 28 (16.1) 1.00 
Central intravenous line 9 (37.5) 67 (38.5) 1.00 
History of broad-spectrum antimicrobial drug exposure§ 4 (16.7) 27 (15.5) 1.00 
Kidney disease, on dialysis 3 (12.5) 5 (2.9) 0.058 
Genitourinary surgery/procedure§ 0 14 (8.1) 0.226 
Gastrointestinal surgery/procedure§ 3 (12.5) 22 (12.6) 1.00 
*Values are no. (%) patients except as indicated. IQR, interquartile range; IVDU, intravenous drug use. 
†In all patients, gender and biological sex were identical. 
‡Includes active chemotherapy, systemic corticosteroid use, and immunosuppression within 3 months before the onset of candidemia. 
§ Procedure performed <30 days before onset of candidemia. 
 
Figure. Distribution of candidemia cases associated with IVDU and 
non-IVDU by year at a tertiary care hospital, Massachusetts, USA, 
2010–2017. Candidemia cases were divided into IVDU and non-
IVDU groups and then plotted as a function of the year the patient 
had positive blood cultures for Candida. There were no positive 
blood cultures in January 2017, the last month of the study.
SYNOPSIS
cases reported in the literature that were associated with in-
jection of brown heroin and the ones in this case series. Cu-
taneous, ocular, or osteoarticular involvement were com-
monly observed in the brown heroin users with candidiasis 
(8,9) but were rarely seen in the IVDU case-patients we 
report. In contrast, although all the cases in our study fea-
tured candidemia by definition, blood cultures were rarely 
positive for candidemia in the brown heroin cases.
As discussed earlier, in the brown heroin cases, the 
infections were linked to C. albicans contamination of 
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Table 2. Summary of characteristics of patients with candidemia and a history of IVDU admitted to a tertiary care hospital, 
Massachusetts, USA, 2010–2017* 
Pt 
no. 
Age, y/ 
sex 
Date 
admitted 
IVDU, 
by history Toxicology screen 
Last use, 
by history 
Candida 
species 
Vegetations 
on echo 
Antifungal therapy 
(duration) Outcome 
1 32/M 2010 Jan Heroin Heroin, 
morphine, cocaine 
5 d C. 
parapsilosis 
No Fluc (14 d) Cured 
2 28/M 2010 Oct Heroin ND 6 mo C. 
parapsilosis 
No Fluc (14 d) Cured 
3 52/F 2012 Jul Heroin, 
cocaine 
Opiates NA C. glabrata No MF (8 d) then fluc 
(20 d) 
Cured 
4 43/F 2012 Oct Heroin Cocaine, 
opiates† 
1.5 d C. 
parapsilosis 
Yes (aortic, 
mitral) 
None Died 
5 59/M 2012 Nov Not 
documented 
ND 30 y C. glabrata No Fluc (14 d) Died 
6 54/M 2013 Mar Heroin, 
cocaine 
Methadone, 
opiates 
2 y C. 
parapsilosis 
No MF (3 d) then fluc 
(25 d) 
Cured 
7 43/F 2013 Apr Heroin ND NA C. albicans No MF (3 d) then 
fluc (25 d) 
Cured 
8 31/M 2013 Aug Heroin Opiates 2 y C. albicans No MF (2 d) then fluc 
(12 d) 
Cured 
9 36/M 2013 Dec Heroin Oxycodone, 
hydromorphone 
6 d C. glabrata, 
C. 
parapsilosis 
No None Lost to 
follow up 
10 49 /F 2014 Jan Unspecified 
narcotic 
Opiates NA C. glabrata No MF (3 d) Died 
11 38/F 2014 Feb Heroin Oxycodone, 
oxymorphone 
2 y C. albicans Possible 
(tricuspid on 
TTE, TEE 
negative) 
Fluc (2 d) then MF 
(40 d) 
Remission 
(had 
epidural 
abscess) 
12 50/M 2014 Aug Heroin Morphine 6 mo C. tropicalis No Fluc (14 d) Cured 
13 49/M 2015 Mar Cocaine ND Unknown C. lipolytica No Fluc (14 d) Cured 
14 22/M 2015 Jun Heroin Marijuana Day 
admitted 
C. glabrata No MF (3 d) then fluc  
(25 d) 
Cured 
15 53/M 2015 Sep Cocaine Cocaine Remote C. tropicalis No Fluc (2 d) Died 
16 31/F 2016 Jan Cocaine Morphine NA C. tropicalis No Fluc (14d) Cured 
17 37/M 2016 Feb Heroin ND 3 wk C. glabrata No Fluc (14d) Cured 
18 35/M 2016 Mar Heroin, 
Cocaine 
Cocaine, opiates† NA C. albicans No MF (4 d) then 
fluc (24 d) 
Cured 
19 44/M 2016 Apr Cocaine, 
heroin 
Buprenorphine, 
norbuprenorphine 
7 mo C. 
parapsilosis 
Yes (aortic) Fluc (indefinite) Remission 
follow up 
TTE after 3 
mo: no 
vegetation 
20 47/M 2016 Apr Cocaine ND 1 y C. albicans No MF (6 d) then fluc 
(8d) 
Cured 
21 32/F 2016 
May 
Heroin Methadone, 
oxycodone 
2 wk C. albicans Yes (mitral) AmpB (1 d) then 
fluc and vori 
(indefinite)‡ 
Remission 
follow up 
TTE after 3 
mo: no 
vegetation 
22 46/M 2016 
May 
Cocaine, 
heroin 
ND Day 
admitted 
C. glabrata No Fluc (21 d) Cured 
23 40/M 2016 Jun Heroin Opiates Day 
admitted 
C. albicans, 
C. glabrata 
No MF (13 d) then 
fluc (1 d) 
Cured 
24 54/M 2016 Sep Heroin ND 1 mo C. 
parapsilosis 
Yes (aortic) MF (5 d) then 
ampB and 5FC (5 
d) 
Died 
*ampB, amphotericin B; 5FC, 5-flucytosine; echo, echocardiogram; fluc, fluconazole; IVDU, intravenous drug use; MF, micafungin; NA, not available; ND, 
not done; Pt, patient; TEE, transesophageal echocardiogram; TTE, transthoracic echocardiogram; vori, voriconazole. 
†Positive toxicology screen was obtained during a previous admission. 
‡Patient developed hypercalcemia after courses of fluconazole and treatment was changed to voriconazole. 
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lemon juice used to solubilize the heroin; blood cultures, 
when positive, grew only C. albicans (8,9). In our case 
series, C. albicans was the third most common species, 
behind C. glabrata and C. parapsilosis. The finding of 
different species of Candida argues against a common 
source of infection. Rather, endogenous sources of Candi-
da seem likely, because this fungus can colonize the skin 
and mouth; injection drug users may lick their needles be-
fore insertion into the skin. However, our IRB protocol 
did not permit us to interview subjects regarding injection 
habits or to culture their drugs and injection parapherna-
lia. Thus, the source of the Candida species isolated from 
the patients is speculative, and future studies are needed 
to address this question.
C. glabrata and C. parapsilosis are typically thought 
of as nosocomial pathogens, with spread of the patho-
gen facilitated by contaminated inanimate surfaces and 
person-to-person contact (15,16). However, both species 
can also be gut colonizers and commensals of human 
skin (16). C. glabrata is often resistant to fluconazole; 
a risk factor for infection with this species is prior re-
ceipt of fluconazole (15). However, none of our patients 
was known to have received fluconazole before contract-
ing candidemia.
In our study, we found that the candidemia patients 
in the IVDU group were younger and more likely to be 
co-infected with hepatitis C than were patients in the 
non-IVDU group. This finding likely reflects the rela-
tively young age of the IVDU population and the high 
prevalence of hepatitis C infection for this group (17). 
Even though more than half of the patients in the IVDU 
group were co-infected with hepatitis C, no patient had 
HIV infection. This finding is consistent with a 2012 re-
port documenting declining rates of HIV infection and 
increasing rates of hepatitis C among injection drug us-
ers in Massachusetts (18).
In a recent multicenter study of >2,000 patients with 
candidemia, C. albicans was responsible for 46% of the 
cases, followed by C. glabrata (26%), C. parapsilosis 
(16%), C. tropicalis (8%), and C. krusei (3%) (1). In our 
study, the species distribution in the non-IVDU popula-
tion with candidemia was very similar, with slightly more 
than half the cases attributable to C. albicans (Table 4). In 
contrast, only 7 (29%) of 24 candidemia cases in the 
IVDU population were caused by C. albicans, and 1 of 
those cases was a co-infection with C. glabrata. Perhaps 
reflecting these patients’ younger age and fewer concur-
rent conditions, the mortality rate was lower for the IVDU 
population compared with the non-IVDU population, al-
though the difference was not statistically significant. 
Nevertheless, 5 (21%) of 24 patients in the IVDU group 
died, emphasizing that candidemia in the IVDU popu-
lation is a serious disease associated with a serious risk 
of death.
Our retrospective study does not shed light on the op-
timal therapy for IVDU-associated candidemia. However, 
it seems reasonable to begin to treat patients with an echi-
nocandin, according to the Infectious Diseases Society of 
America clinical practice guideline for the treatment of 
candidemia (19), pending identification and susceptibility 
testing of the isolate. One third of our IVDU-associated 
candidemia cases were caused by C. glabrata which, as 
noted earlier, is often resistant to fluconazole (15). In ad-
dition, the superiority of an echinocandin over fluconazole 
was demonstrated in a multicenter trial of patients with 
candidemia (20). However, a disadvantage of the echino-
candins is their need to be given intravenously, a particular 
problem in the patient population with IVDU, because they 
may use intravenous lines for drug injection. In clinically 
stable patients with susceptible isolates and without endo-
carditis, transition to fluconazole can be considered when 
the patient is ready for discharge.
Several limitations should be taken into account 
when interpreting the data we present. The study was 
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Table 3. Organ system involvement in patients with candidemia 
at a tertiary care hospital, Massachusetts, USA, 2010–2017* 
Manifestation 
No. (%) patients 
p value 
IVDU,  
n = 24 
Non-IVDU,  
n = 174 
Endocarditis 4 (16.7) 5 (2.9) 0.014 
Brain abscess 1 (4.2) 0 0.121 
Septic emboli, lung 1 (4.2) 0 0.121 
Retinitis 0 4 (2.3) 1.00 
Osteomyelitis 2 (8.3) 0 0.014 
*IVDU, intravenous drug use. 
 
 
Table 4. Candida species isolated from blood of patients with 
candidemia at a tertiary care hospital, Massachusetts, USA, 
2010–2017* 
Organisms 
No. (%) patients 
p value IVDU, n = 24 Non-IVDU, n = 174 
C. albicans 7 (29.2)† 93 (53.5) 0.03 
C. glabrata 8 (33.3) 39 (22.4) 0.304 
C. parapsilosis 8 (33.3) 25 (14.4) 0.036 
C. tropicalis 3 (12.5) 13 (7.5) 0.419 
C. dubliniensis 0 2 (1.2) 1.00 
C. guilliermondii 0 1 (0.6) 1.00 
C. krusei 0 1 (0.6) 1.00 
C. lipolytica 0 1 (0.6) 1.00 
C. kefyr 0 1 (0.6) 1.00 
Co-infected 2 (8.3) 2 (1.2) 0.073 
*IVDU, intravenous drug use. 
†Percentages do not add up to 100% because patients co-infected with 2 
species are counted twice. 
 
 
Table 5. Outcomes of patients with candidemia, Massachusetts, 
USA, 2010–2017* 
Outcome 
IVDU,  
n = 24 
Non-IVDU, 
n = 174 p value 
Death, no. (%) patients 5 (20.8) 60 (34.5) 0.247 
Median length of hospital 
stay (IQR), d 
11 (17.5) 19 (27.5) 0.059 
*IQR, interquartile range; IVDU, intravenous drug use. 
 
SYNOPSIS
retrospective, and because of our IRB protocol, we were 
not permitted to contact the patients directly to verify their 
histories or obtain additional information. Moreover, it 
is often difficult to obtain an accurate history of IVDU 
from patients. Thus, because it was not known whether 
the injection drug use was current or not, we cannot be 
certain that the IVDU contributed to the risk of develop-
ing candidemia. Indeed, it is possible that some of the pa-
tients were misclassified and there may be inaccuracies in 
variables such as when the patients last injected drugs and 
what drugs were injected. For this reason, when designing 
the study, we prospectively decided to include all patients 
with a history of IVDU, however remote, in the IVDU 
group. Second, although it is very likely that the trend to-
ward increasing numbers of IVDU-associated candidemia 
is real, it is possible that the way IVDU is recorded has 
changed over the years because healthcare providers are 
now more attuned to the opioid epidemic and thus record 
the history of IVDU more often than they did in the past. 
Third, although the number of cases was relatively large, 
the study was not powered to detect differences in uncom-
mon events between the IVDU and non-IVDU groups. 
In addition, multivariate analyses were not performed, 
so some statistically significant associations may be con-
founded. Fourth, there may have been a bias toward order-
ing certain tests, such as hepatitis C serology and echo-
cardiography, in the IVDU-associated candidemia group. 
Finally, our study was a single-center study from a tertiary 
care institution. It remains to be seen whether candidemia 
in IVDU is mostly a local phenomenon peculiar to central 
Massachusetts or it is emerging at other medical centers in 
other geographic locations.
These limitations notwithstanding, our findings es-
tablish candidemia as an underappreciated outcome of the 
opioid epidemic gripping the United States. Moreover, 
we observed a marked increase in the number of cases 
during the last year of the study. Although this finding 
may reflect random variations, it is of concern that the 
problem may be worsening. In Worcester County, where 
UMassMemorial Hospital is located, the number of opi-
oid-related overdose deaths increased every year during 
the 7-year study period, from 80 in 2010 to 251 in 2016 
(7). Although many of the press reports surrounding il-
licit opioid use have centered on deaths from overdose, 
infections remain a serious cause of illness and death in 
persons with IVDU. Invasive candidiasis must be consid-
ered in the differential diagnosis of patients with infec-
tious sequelae of IVDU.
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